LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Accueil・Liste d'Actions・Sanofi

Sanofi

Ouvert

53.04 -0.39

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

52.97

Max

53.52

Chiffres clés
By Trading Economics
Revenu	1.7B 2.8B
Ventes	2.8B 14B
P/E Moyenne du Secteur	30.71 104.138
BPA	2.25
Marge bénéficiaire	19.884
EBITDA	2.2B 4.2B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+22.02 upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	136B
Ouverture précédente	53.43
Clôture précédente	53.04

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

52.4 / 52.98 Support & Résistance

Sanofi Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 oct. 2024, 16:07 UTC

Acquisitions, Fusions, Rachats

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

25 oct. 2024, 05:44 UTC

Résultats

Sanofi Profit, Sales Beat Estimates

21 oct. 2024, 08:29 UTC

Acquisitions, Fusions, Rachats

Sanofi Enters Exclusive Talks With CD&R Over Consumer Business Stake Sale -- 2nd Update

21 oct. 2024, 06:31 UTC

Acquisitions, Fusions, Rachats

Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale -- Update

21 oct. 2024, 06:13 UTC

Acquisitions, Fusions, Rachats

Sanofi Expects Faster Earnings Growth Without Opella

21 oct. 2024, 06:02 UTC

Acquisitions, Fusions, Rachats

Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale

17 oct. 2024, 16:21 UTC

Acquisitions, Fusions, Rachats

PAI Partners Submits Improved Bid on Sanofi's Consumer Unit

16 oct. 2024, 16:03 UTC

Acquisitions, Fusions, Rachats

Sanofi in Talks With French Government to Address Concerns on Opella Deal

11 oct. 2024, 11:33 UTC

Acquisitions, Fusions, Rachats

Sanofi in Talks to Sell Controlling Stake in Consumer Health Arm to CD&R -- 2nd Update

25 oct. 2024, 20:25 UTC

Résultats

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct. 2024, 13:12 UTC

Résultats

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct. 2024, 07:00 UTC

Market Talk

Résultats

Acquisitions, Fusions, Rachats

Sanofi's 3Q Results Show Solid Vaccine Performance -- Market Talk

25 oct. 2024, 05:30 UTC

Résultats

Sanofi 3Q Adj EPS EUR2.86

25 oct. 2024, 05:30 UTC

Résultats

Sanofi 3Q FCF EUR3.33B

25 oct. 2024, 05:30 UTC

Résultats

Analysts Saw Sanofi 3Q Business Operating Income at EUR4.03B

25 oct. 2024, 05:30 UTC

Résultats

Sanofi 3Q Business Net Profit EUR3.59B

25 oct. 2024, 05:30 UTC

Résultats

Sanofi 3Q Sales EUR13.44B

25 oct. 2024, 05:30 UTC

Résultats

Analysts Saw Sanofi 3Q Sales at EUR12.63B

25 oct. 2024, 05:30 UTC

Résultats

Sanofi 3Q Business Operating Profit EUR4.61B

21 oct. 2024, 21:02 UTC

Acquisitions, Fusions, Rachats

Sanofi Deal Jitters Imperil Stock's Big Rebound -- Barrons.com

21 oct. 2024, 08:52 UTC

Actions en Tendance

Stocks to Watch Monday: Boeing, Kenvue and Walmart -- WSJ

21 oct. 2024, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi: Proposed Transaction Is Subject to Finalization of Agreements, Approvals

21 oct. 2024, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi Adjusts 2024 View After Opella Update

21 oct. 2024, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi: Bpifrance Expected to Participate in Deal With 2% Stake in Opella

21 oct. 2024, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi Expects 2024 Business EPS to Grow by at Least Low-Single Digit Excluding Opella

21 oct. 2024, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi In Talks to Sell 50% Stake in Opella to CD&R

21 oct. 2024, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi to Remain Significant Shareholder in Opella

21 oct. 2024, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi, CD&R Talks Value Opella at Enterprise Value of About EUR16B

21 oct. 2024, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi, CD&R in Exclusive Negotiations for Sale, Purchase of 50% Stake in Opella

16 oct. 2024, 10:33 UTC

Market Talk

Acquisitions, Fusions, Rachats

Sanofi Needs Clear Consumer Health Plan as Investors Concerns Mount -- Market Talk

Comparaison

Variation de prix

Sanofi prévision

Objectif de Prix

By TipRanks

22.02% hausse

Prévisions sur 12 Mois

Moyen 65 USD 22.02%

Haut 67 USD

Bas 63 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

Achat

Maintien

Vente

Basé sur 3 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

52.4 / 52.98Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Sanofi

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.